Carbon Ion Radiotherapy in Advanced Hypofractionated Regimens for Prostate Cancer: From 20 to 16 Fractions
Purpose To assess the effects of differences in dose fractionation on late radiation toxicity and biochemical control in patients with prostate cancer treated with carbon ion radiotherapy (C-ion RT). Methods and Materials A total of 740 prostate cancer patients who received C-ion RT between April 20...
Gespeichert in:
| Veröffentlicht in: | International journal of radiation oncology, biology, physics biology, physics, 2012-11, Vol.84 (4), p.968-972 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 972 |
|---|---|
| container_issue | 4 |
| container_start_page | 968 |
| container_title | International journal of radiation oncology, biology, physics |
| container_volume | 84 |
| creator | Okada, Tohru, MD, PhD Tsuji, Hiroshi, MD, PhD Kamada, Tadashi, MD, PhD Akakura, Koichiro, MD, PhD Suzuki, Hiroyoshi, MD, PhD Shimazaki, Jun, MD, PhD Tsujii, Hirohiko, MD, PhD |
| description | Purpose To assess the effects of differences in dose fractionation on late radiation toxicity and biochemical control in patients with prostate cancer treated with carbon ion radiotherapy (C-ion RT). Methods and Materials A total of 740 prostate cancer patients who received C-ion RT between April 2000 and February 2009 were analyzed. Of those, 664 patients followed for at least 1 year were analyzed with regard to late radiation toxicity. Biochemical relapse-free (BRF) and overall survival (OS) rates in patient subgroups with each dose-fractionation were analyzed. Results Only 1 case of grade 3 genitourinary (GU) morbidity was observed in 20 fractions, and none of the patients developed higher grade morbidities. The incidence of late GU toxicity in patients treated with 16 fractions was lower than that of patients treated with 20 fractions. The OS rate and BRF rate of the entire group at 5 years were 95.2% and 89.7%, respectively. The 5-year BRF rate of the patients treated with 16 fractions of C-ion RT (88.5%) was comparable to that of the patients treated with 20 fractions (90.2%). Conclusion C-ion RT of 57.6 GyE (the physical C-ion dose [Gy] × RBE) in 16 fractions could offer an even lower incidence of genitourinary toxicity and comparable BRF rate than that in 20 fractions. Advancement in hypofractionation could be safely achieved with C-ion RT for prostate cancer. |
| doi_str_mv | 10.1016/j.ijrobp.2012.01.072 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_osti_</sourceid><recordid>TN_cdi_osti_scitechconnect_22149636</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0360301612001459</els_id><sourcerecordid>1492606042</sourcerecordid><originalsourceid>FETCH-LOGICAL-c618t-534dab3e80acb2b83bdd0d3ce4081d0bf7b81fe35340c3c363bd9732dc326ba23</originalsourceid><addsrcrecordid>eNqFkl2LEzEUhoMobq3-A5GACN5MPUmmmRkvhKW4H7CgrArehXyNm7FNajJd6L_fM0xV8MaLEBKe93y9h5CXDFYMmHw3rMKQk9mvODC-AraChj8iC9Y2XSXW6--PyQKEhEogfEaelTIAAGNN_ZSccd52rWhhQYaNziZFeo3nVruQxjuf9f5IQ6Tn7l5H6x29Ou5Tn7UdQ4p6xI9b_yPsfCy0T5l-zqmM-E03E53f04ucdpQDHRNlEl-zsDwnT3q9Lf7F6V6Sbxcfv26uqptPl9eb85vKStaO1VrUThvhW9DWcNMK4xw4YX0NLXNg-sa0rPcCObDCColA1wjurODSaC6W5PUcF8sKqtgwentnU4zejopzVncSRUvydqb2Of06-DKqXSjWb7c6-nQoCjEuQUI9Baxn1GKnJfte7XPY6XxUDNTkhRrU7IWavFDAFHqBslenDAez8-6P6PfwEXhzAnSxeosTjjaUv5yUfN3JDrkPM-dxavfB56kpPzkT8tSTS-F_lfwbwG5DDJjzpz_6MqRDjuiIYqqgRn2Z9mZaG8ZxY-p1Jx4Al1u9Qg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1492606042</pqid></control><display><type>article</type><title>Carbon Ion Radiotherapy in Advanced Hypofractionated Regimens for Prostate Cancer: From 20 to 16 Fractions</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Okada, Tohru, MD, PhD ; Tsuji, Hiroshi, MD, PhD ; Kamada, Tadashi, MD, PhD ; Akakura, Koichiro, MD, PhD ; Suzuki, Hiroyoshi, MD, PhD ; Shimazaki, Jun, MD, PhD ; Tsujii, Hirohiko, MD, PhD</creator><creatorcontrib>Okada, Tohru, MD, PhD ; Tsuji, Hiroshi, MD, PhD ; Kamada, Tadashi, MD, PhD ; Akakura, Koichiro, MD, PhD ; Suzuki, Hiroyoshi, MD, PhD ; Shimazaki, Jun, MD, PhD ; Tsujii, Hirohiko, MD, PhD ; Working Group for Genitourinary Tumors</creatorcontrib><description>Purpose To assess the effects of differences in dose fractionation on late radiation toxicity and biochemical control in patients with prostate cancer treated with carbon ion radiotherapy (C-ion RT). Methods and Materials A total of 740 prostate cancer patients who received C-ion RT between April 2000 and February 2009 were analyzed. Of those, 664 patients followed for at least 1 year were analyzed with regard to late radiation toxicity. Biochemical relapse-free (BRF) and overall survival (OS) rates in patient subgroups with each dose-fractionation were analyzed. Results Only 1 case of grade 3 genitourinary (GU) morbidity was observed in 20 fractions, and none of the patients developed higher grade morbidities. The incidence of late GU toxicity in patients treated with 16 fractions was lower than that of patients treated with 20 fractions. The OS rate and BRF rate of the entire group at 5 years were 95.2% and 89.7%, respectively. The 5-year BRF rate of the patients treated with 16 fractions of C-ion RT (88.5%) was comparable to that of the patients treated with 20 fractions (90.2%). Conclusion C-ion RT of 57.6 GyE (the physical C-ion dose [Gy] × RBE) in 16 fractions could offer an even lower incidence of genitourinary toxicity and comparable BRF rate than that in 20 fractions. Advancement in hypofractionation could be safely achieved with C-ion RT for prostate cancer.</description><identifier>ISSN: 0360-3016</identifier><identifier>EISSN: 1879-355X</identifier><identifier>DOI: 10.1016/j.ijrobp.2012.01.072</identifier><identifier>PMID: 22898380</identifier><identifier>CODEN: IOBPD3</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adenocarcinoma - blood ; Adenocarcinoma - mortality ; Adenocarcinoma - pathology ; Adenocarcinoma - radiotherapy ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Carbon ; Carbon - adverse effects ; Carbon - therapeutic use ; Carbon ion radiotherapy ; CARBON IONS ; DISEASE INCIDENCE ; Dose Fractionation ; FRACTIONATED IRRADIATION ; Gynecology. Andrology. Obstetrics ; Heavy Ion Radiotherapy - adverse effects ; Heavy Ion Radiotherapy - methods ; Hematology, Oncology and Palliative Medicine ; Humans ; Hypofractionation ; Male ; Male genital diseases ; Medical sciences ; Middle Aged ; Neoplasm Staging ; NEOPLASMS ; Nephrology. Urinary tract diseases ; PATIENTS ; PROSTATE ; Prostate cancer ; Prostate-Specific Antigen - blood ; Prostatic Neoplasms - blood ; Prostatic Neoplasms - mortality ; Prostatic Neoplasms - pathology ; Prostatic Neoplasms - radiotherapy ; RADIATION DOSES ; Radiation Injuries - pathology ; Radiology ; RADIOLOGY AND NUCLEAR MEDICINE ; RADIOTHERAPY ; Rectum - radiation effects ; Retrospective Studies ; Survival Rate ; TOXICITY ; Tumors ; Tumors of the urinary system ; Urinary tract. Prostate gland ; Urogenital System - radiation effects</subject><ispartof>International journal of radiation oncology, biology, physics, 2012-11, Vol.84 (4), p.968-972</ispartof><rights>Elsevier Inc.</rights><rights>2012 Elsevier Inc.</rights><rights>2014 INIST-CNRS</rights><rights>Copyright © 2012 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c618t-534dab3e80acb2b83bdd0d3ce4081d0bf7b81fe35340c3c363bd9732dc326ba23</citedby><cites>FETCH-LOGICAL-c618t-534dab3e80acb2b83bdd0d3ce4081d0bf7b81fe35340c3c363bd9732dc326ba23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0360301612001459$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26625969$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22898380$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/22149636$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Okada, Tohru, MD, PhD</creatorcontrib><creatorcontrib>Tsuji, Hiroshi, MD, PhD</creatorcontrib><creatorcontrib>Kamada, Tadashi, MD, PhD</creatorcontrib><creatorcontrib>Akakura, Koichiro, MD, PhD</creatorcontrib><creatorcontrib>Suzuki, Hiroyoshi, MD, PhD</creatorcontrib><creatorcontrib>Shimazaki, Jun, MD, PhD</creatorcontrib><creatorcontrib>Tsujii, Hirohiko, MD, PhD</creatorcontrib><creatorcontrib>Working Group for Genitourinary Tumors</creatorcontrib><title>Carbon Ion Radiotherapy in Advanced Hypofractionated Regimens for Prostate Cancer: From 20 to 16 Fractions</title><title>International journal of radiation oncology, biology, physics</title><addtitle>Int J Radiat Oncol Biol Phys</addtitle><description>Purpose To assess the effects of differences in dose fractionation on late radiation toxicity and biochemical control in patients with prostate cancer treated with carbon ion radiotherapy (C-ion RT). Methods and Materials A total of 740 prostate cancer patients who received C-ion RT between April 2000 and February 2009 were analyzed. Of those, 664 patients followed for at least 1 year were analyzed with regard to late radiation toxicity. Biochemical relapse-free (BRF) and overall survival (OS) rates in patient subgroups with each dose-fractionation were analyzed. Results Only 1 case of grade 3 genitourinary (GU) morbidity was observed in 20 fractions, and none of the patients developed higher grade morbidities. The incidence of late GU toxicity in patients treated with 16 fractions was lower than that of patients treated with 20 fractions. The OS rate and BRF rate of the entire group at 5 years were 95.2% and 89.7%, respectively. The 5-year BRF rate of the patients treated with 16 fractions of C-ion RT (88.5%) was comparable to that of the patients treated with 20 fractions (90.2%). Conclusion C-ion RT of 57.6 GyE (the physical C-ion dose [Gy] × RBE) in 16 fractions could offer an even lower incidence of genitourinary toxicity and comparable BRF rate than that in 20 fractions. Advancement in hypofractionation could be safely achieved with C-ion RT for prostate cancer.</description><subject>Adenocarcinoma - blood</subject><subject>Adenocarcinoma - mortality</subject><subject>Adenocarcinoma - pathology</subject><subject>Adenocarcinoma - radiotherapy</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Carbon</subject><subject>Carbon - adverse effects</subject><subject>Carbon - therapeutic use</subject><subject>Carbon ion radiotherapy</subject><subject>CARBON IONS</subject><subject>DISEASE INCIDENCE</subject><subject>Dose Fractionation</subject><subject>FRACTIONATED IRRADIATION</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Heavy Ion Radiotherapy - adverse effects</subject><subject>Heavy Ion Radiotherapy - methods</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Hypofractionation</subject><subject>Male</subject><subject>Male genital diseases</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>NEOPLASMS</subject><subject>Nephrology. Urinary tract diseases</subject><subject>PATIENTS</subject><subject>PROSTATE</subject><subject>Prostate cancer</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatic Neoplasms - blood</subject><subject>Prostatic Neoplasms - mortality</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Prostatic Neoplasms - radiotherapy</subject><subject>RADIATION DOSES</subject><subject>Radiation Injuries - pathology</subject><subject>Radiology</subject><subject>RADIOLOGY AND NUCLEAR MEDICINE</subject><subject>RADIOTHERAPY</subject><subject>Rectum - radiation effects</subject><subject>Retrospective Studies</subject><subject>Survival Rate</subject><subject>TOXICITY</subject><subject>Tumors</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><subject>Urogenital System - radiation effects</subject><issn>0360-3016</issn><issn>1879-355X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkl2LEzEUhoMobq3-A5GACN5MPUmmmRkvhKW4H7CgrArehXyNm7FNajJd6L_fM0xV8MaLEBKe93y9h5CXDFYMmHw3rMKQk9mvODC-AraChj8iC9Y2XSXW6--PyQKEhEogfEaelTIAAGNN_ZSccd52rWhhQYaNziZFeo3nVruQxjuf9f5IQ6Tn7l5H6x29Ou5Tn7UdQ4p6xI9b_yPsfCy0T5l-zqmM-E03E53f04ucdpQDHRNlEl-zsDwnT3q9Lf7F6V6Sbxcfv26uqptPl9eb85vKStaO1VrUThvhW9DWcNMK4xw4YX0NLXNg-sa0rPcCObDCColA1wjurODSaC6W5PUcF8sKqtgwentnU4zejopzVncSRUvydqb2Of06-DKqXSjWb7c6-nQoCjEuQUI9Baxn1GKnJfte7XPY6XxUDNTkhRrU7IWavFDAFHqBslenDAez8-6P6PfwEXhzAnSxeosTjjaUv5yUfN3JDrkPM-dxavfB56kpPzkT8tSTS-F_lfwbwG5DDJjzpz_6MqRDjuiIYqqgRn2Z9mZaG8ZxY-p1Jx4Al1u9Qg</recordid><startdate>20121115</startdate><enddate>20121115</enddate><creator>Okada, Tohru, MD, PhD</creator><creator>Tsuji, Hiroshi, MD, PhD</creator><creator>Kamada, Tadashi, MD, PhD</creator><creator>Akakura, Koichiro, MD, PhD</creator><creator>Suzuki, Hiroyoshi, MD, PhD</creator><creator>Shimazaki, Jun, MD, PhD</creator><creator>Tsujii, Hirohiko, MD, PhD</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope><scope>OTOTI</scope></search><sort><creationdate>20121115</creationdate><title>Carbon Ion Radiotherapy in Advanced Hypofractionated Regimens for Prostate Cancer: From 20 to 16 Fractions</title><author>Okada, Tohru, MD, PhD ; Tsuji, Hiroshi, MD, PhD ; Kamada, Tadashi, MD, PhD ; Akakura, Koichiro, MD, PhD ; Suzuki, Hiroyoshi, MD, PhD ; Shimazaki, Jun, MD, PhD ; Tsujii, Hirohiko, MD, PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c618t-534dab3e80acb2b83bdd0d3ce4081d0bf7b81fe35340c3c363bd9732dc326ba23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adenocarcinoma - blood</topic><topic>Adenocarcinoma - mortality</topic><topic>Adenocarcinoma - pathology</topic><topic>Adenocarcinoma - radiotherapy</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Carbon</topic><topic>Carbon - adverse effects</topic><topic>Carbon - therapeutic use</topic><topic>Carbon ion radiotherapy</topic><topic>CARBON IONS</topic><topic>DISEASE INCIDENCE</topic><topic>Dose Fractionation</topic><topic>FRACTIONATED IRRADIATION</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Heavy Ion Radiotherapy - adverse effects</topic><topic>Heavy Ion Radiotherapy - methods</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Hypofractionation</topic><topic>Male</topic><topic>Male genital diseases</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>NEOPLASMS</topic><topic>Nephrology. Urinary tract diseases</topic><topic>PATIENTS</topic><topic>PROSTATE</topic><topic>Prostate cancer</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatic Neoplasms - blood</topic><topic>Prostatic Neoplasms - mortality</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Prostatic Neoplasms - radiotherapy</topic><topic>RADIATION DOSES</topic><topic>Radiation Injuries - pathology</topic><topic>Radiology</topic><topic>RADIOLOGY AND NUCLEAR MEDICINE</topic><topic>RADIOTHERAPY</topic><topic>Rectum - radiation effects</topic><topic>Retrospective Studies</topic><topic>Survival Rate</topic><topic>TOXICITY</topic><topic>Tumors</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><topic>Urogenital System - radiation effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Okada, Tohru, MD, PhD</creatorcontrib><creatorcontrib>Tsuji, Hiroshi, MD, PhD</creatorcontrib><creatorcontrib>Kamada, Tadashi, MD, PhD</creatorcontrib><creatorcontrib>Akakura, Koichiro, MD, PhD</creatorcontrib><creatorcontrib>Suzuki, Hiroyoshi, MD, PhD</creatorcontrib><creatorcontrib>Shimazaki, Jun, MD, PhD</creatorcontrib><creatorcontrib>Tsujii, Hirohiko, MD, PhD</creatorcontrib><creatorcontrib>Working Group for Genitourinary Tumors</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>OSTI.GOV</collection><jtitle>International journal of radiation oncology, biology, physics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Okada, Tohru, MD, PhD</au><au>Tsuji, Hiroshi, MD, PhD</au><au>Kamada, Tadashi, MD, PhD</au><au>Akakura, Koichiro, MD, PhD</au><au>Suzuki, Hiroyoshi, MD, PhD</au><au>Shimazaki, Jun, MD, PhD</au><au>Tsujii, Hirohiko, MD, PhD</au><aucorp>Working Group for Genitourinary Tumors</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Carbon Ion Radiotherapy in Advanced Hypofractionated Regimens for Prostate Cancer: From 20 to 16 Fractions</atitle><jtitle>International journal of radiation oncology, biology, physics</jtitle><addtitle>Int J Radiat Oncol Biol Phys</addtitle><date>2012-11-15</date><risdate>2012</risdate><volume>84</volume><issue>4</issue><spage>968</spage><epage>972</epage><pages>968-972</pages><issn>0360-3016</issn><eissn>1879-355X</eissn><coden>IOBPD3</coden><abstract>Purpose To assess the effects of differences in dose fractionation on late radiation toxicity and biochemical control in patients with prostate cancer treated with carbon ion radiotherapy (C-ion RT). Methods and Materials A total of 740 prostate cancer patients who received C-ion RT between April 2000 and February 2009 were analyzed. Of those, 664 patients followed for at least 1 year were analyzed with regard to late radiation toxicity. Biochemical relapse-free (BRF) and overall survival (OS) rates in patient subgroups with each dose-fractionation were analyzed. Results Only 1 case of grade 3 genitourinary (GU) morbidity was observed in 20 fractions, and none of the patients developed higher grade morbidities. The incidence of late GU toxicity in patients treated with 16 fractions was lower than that of patients treated with 20 fractions. The OS rate and BRF rate of the entire group at 5 years were 95.2% and 89.7%, respectively. The 5-year BRF rate of the patients treated with 16 fractions of C-ion RT (88.5%) was comparable to that of the patients treated with 20 fractions (90.2%). Conclusion C-ion RT of 57.6 GyE (the physical C-ion dose [Gy] × RBE) in 16 fractions could offer an even lower incidence of genitourinary toxicity and comparable BRF rate than that in 20 fractions. Advancement in hypofractionation could be safely achieved with C-ion RT for prostate cancer.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>22898380</pmid><doi>10.1016/j.ijrobp.2012.01.072</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0360-3016 |
| ispartof | International journal of radiation oncology, biology, physics, 2012-11, Vol.84 (4), p.968-972 |
| issn | 0360-3016 1879-355X |
| language | eng |
| recordid | cdi_osti_scitechconnect_22149636 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adenocarcinoma - blood Adenocarcinoma - mortality Adenocarcinoma - pathology Adenocarcinoma - radiotherapy Aged Aged, 80 and over Biological and medical sciences Carbon Carbon - adverse effects Carbon - therapeutic use Carbon ion radiotherapy CARBON IONS DISEASE INCIDENCE Dose Fractionation FRACTIONATED IRRADIATION Gynecology. Andrology. Obstetrics Heavy Ion Radiotherapy - adverse effects Heavy Ion Radiotherapy - methods Hematology, Oncology and Palliative Medicine Humans Hypofractionation Male Male genital diseases Medical sciences Middle Aged Neoplasm Staging NEOPLASMS Nephrology. Urinary tract diseases PATIENTS PROSTATE Prostate cancer Prostate-Specific Antigen - blood Prostatic Neoplasms - blood Prostatic Neoplasms - mortality Prostatic Neoplasms - pathology Prostatic Neoplasms - radiotherapy RADIATION DOSES Radiation Injuries - pathology Radiology RADIOLOGY AND NUCLEAR MEDICINE RADIOTHERAPY Rectum - radiation effects Retrospective Studies Survival Rate TOXICITY Tumors Tumors of the urinary system Urinary tract. Prostate gland Urogenital System - radiation effects |
| title | Carbon Ion Radiotherapy in Advanced Hypofractionated Regimens for Prostate Cancer: From 20 to 16 Fractions |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T14%3A04%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_osti_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Carbon%20Ion%20Radiotherapy%20in%20Advanced%20Hypofractionated%20Regimens%20for%20Prostate%20Cancer:%20From%2020%20to%2016%20Fractions&rft.jtitle=International%20journal%20of%20radiation%20oncology,%20biology,%20physics&rft.au=Okada,%20Tohru,%20MD,%20PhD&rft.aucorp=Working%20Group%20for%20Genitourinary%20Tumors&rft.date=2012-11-15&rft.volume=84&rft.issue=4&rft.spage=968&rft.epage=972&rft.pages=968-972&rft.issn=0360-3016&rft.eissn=1879-355X&rft.coden=IOBPD3&rft_id=info:doi/10.1016/j.ijrobp.2012.01.072&rft_dat=%3Cproquest_osti_%3E1492606042%3C/proquest_osti_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1492606042&rft_id=info:pmid/22898380&rft_els_id=1_s2_0_S0360301612001459&rfr_iscdi=true |